“RDA: better chemotherapy management”

1. “RDA: better chemotherapy management” Investor Presentation April 2013

2. Would you prefer to know if your chemotherapy is working or not NOW OR Would you like to endure 26 weeks of chemotherapy side effects?

3. Problem: Adverse Side Effects • 50% of breast cancer patients receive chemotherapy • 75% of chemo patients derive no long term benefit • All patients suffer adverse side effects

4. Solution:RDA™ improved chemotherapy management • First “Real Time” chemotherapy guidance tool • Only prognostic test to measure response to chemotherapy early in treatment • Discovered in clinical trial (NCIC MA.22) • Protected by broad patents

5. Benefits for Patients, Physicians and Payers • For non responding patients, treatment can be altered quickly • Significant reduction in adverse effects • Switch to alternate treatment improves survival benefit • Objective & useful tool for physicians • Cost savings for healthcare payers ($20k - $60K / patient) “RDA holds the prospect of providing oncologists with an extremely valuable method for managing the chemotherapy of their breast cancer patients” Maureen E. Trudeau MD, FRCPC Head, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Centre, Head, Systemic Therapy Program, Odette Cancer Centre, Toronto, Canada

6. Technology : RNA Disruption Assay (RDA™) National Cancer Institute of Canada breast cancer trial (MA.22) Clear discrimination between responders and non-responders RDA strongly correlates with pathological complete response (pCR) at end of therapy Negative Predictive Value = 0.99 False Negative 1% RDA™ Performance Characteristics

7. RDA™ Clinical Scoring

8. RDA: Clinical System Breast tumour biopsy Fine Needle Aspirate, 2 samples Chemotherapy selected Chemotherapy infusion Raw data analysed by Rna DIAGNOSTICS using proprietary algorithms. Results transmitted to clinician RNA Disruption analysed at Rna DIAGNOSTICS central lab Tumour RNA Fixative

9. Management Team Management • CEO: Dr. Ken Pritzker, MD, FRCPC • Former Chief Pathology & Lab Medicine, Mount Sinai Hospital, Toronto, Cancer diagnostics expert • CSO: Dr. Amadeo Parissenti, PhD • Cancer Research Scientist, Laurentian University • VP Corporate Development: John Connolly, MBA • Former partner at MDS Capital Corp. – 15 year Medtech entrepreneur • CFO: John Jordan, MBA, CMA, CPA, ABV • Financial executive, experienced working with high growth technology companies Clinical Advisory Board • Maureen Trudeau, MA, MD, FRCPC - Head , Medical Oncology, Sunnybrook Health Sciences, Toronto, Canada • Michael Untch, MD, PhD– Head , German Breast Group, Berlin, Germany • Gunter von Minckwitz, MD, PhD – Chairman, German Breast Group, Frankfurt, Germany • Harry Bear, MD, PhD – Principal Investigator, NSABP, Virginia Commonwealth University, USA

10. Market Opportunity in Breast Cancer Total Addressable Market $525M 350,000 $100 M Size of Breast Cancer Market # of Patients per yearin the developed world Sales Forecast by 2018

11. Competition :Oncologists need better tools Physical Exam • Physical Exams do not predict efficacy • Gene panels predict probability of 10 year recurrence • Don’t predict efficacy • Imaging Over estimates efficacy • Too late to impact clinical decision making

12. Sales Forecast

13. Rna Diagnostics Inc. • Unique solution for serious cancer problem • Large market - $500M in Breast Cancer • Strong IP and clinical data • Clinical trials underway • Rapid route to market

14. “RDA: better chemotherapy management” Investor Presentation April 2013